MAPT and dementia: To validate the dementia outcome, we examined plasma phosphorylated tau 217 (p-tau217), an established biomarker for early AD diagnosis24, in 103 NHS participants and found an approximately 3-fold higher dementia risk comparing the highest and lowest quartiles of p-tau217.